Rigel Pharmaceuticals is a biotechnology company focused on the discovery and development of innovative therapies for the treatment of various diseases, particularly those with unmet medical needs
The company specializes in molecular medicine, utilizing advanced technology to create targeted treatments for conditions such as cancer and immune disorders. Through its research initiatives, Rigel aims to deliver effective solutions that improve patient outcomes and enhance the quality of life for individuals facing challenging health issues.
The intense retail focus on Anavex reflects a broader market interest in neurodegenerative therapies, especially following disappointing trial results from Cassava Sciences’ simufilam.
RIGL stock results show that Rigel Pharmaceuticals missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.
U.S. stock futures traded slightly higher this morning. Here are some big stocks recording losses in today’s pre-market trading session. Boot Barn Holdings, Inc. (NYSEBOOT) shares dropped 15.8% to $62.99 in pre-market after the company issued weak financial guidance for Q1 and FY24.
Gainers Kimball International, Inc. (NASDAQKBAL) shares jumped 84.9% to $12.40 after HNI Corporation announced it will acquire the company for $485 million.
